Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- manufacturers
- Mardepodect
-
- $36.00
-
2026-07-17
- CAS:898562-94-2
- Purity: 99.94%
- Supply Ability: 10g
|
| | Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- Basic information |
| Product Name: | Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- | | Synonyms: | MP 10;2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline trihydrochloride;2-({4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline;Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-;2-[(4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl]quinoline;EOS-61169;MP 10, Mardepodect;PF-2545920; PF 2545920; PF2545920; MP-10; MP10; MP 10, MARDEPODECT | | CAS: | 898562-94-2 | | MF: | C25H20N4O | | MW: | 392.45 | | EINECS: | | | Product Categories: | APIs | | Mol File: | 898562-94-2.mol | ![Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- Structure](CAS/GIF/898562-94-2.gif) |
| | Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- Chemical Properties |
| Melting point | 180-181 °C | | Boiling point | 568.6±50.0 °C(Predicted) | | density | 1.21±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMF:PBS (pH 7.2) (1:20): 0.05 mg/ml; DMSO: 15 mg/ml; Ethanol: 0.5 mg/ml | | form | A crystalline solid | | pka | 4.32±0.10(Predicted) | | color | White to off-white | | InChI | 1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3 | | InChIKey | AZEXWHKOMMASPA-UHFFFAOYSA-N | | SMILES | CN1C=C(C2=CC=NC=C2)C(C(C=C3)=CC=C3OCC4=NC5=CC=CC=C5C=C4)=N1.[H]Cl |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- Usage And Synthesis |
| Biological Activity | PF-2545920 hydrochloride (MP-10) is a potent and selective cyclic nucleotide phosphodiesterase (PDE) 10A competitive inhibitor with a reported IC50 value of 1.26 nM. PDE10A hydrolyzes both cAMP and cGMP, and is highly expressed in medium spiny neurons of the mammalian striatum and in basal ganglia areas where D1 and D2 dopamine receptors are expressed. PF-2545920 has been studied for treatment of schizophrenia and Huntingtonμs disease. |
| | Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]- Preparation Products And Raw materials |
|